# Real-World Effectiveness of Rosuvastatin–Ezetimibe Single Pill (Rovazet®) in Korean Dyslipidemia Patients

## TL;DR

This study shows that Rovazet® effectively improves cholesterol levels and is well-tolerated in Korean patients with dyslipidemia.

## Contribution

The study provides real-world evidence on the effectiveness and safety of Rovazet® in a large Korean population.

## Key findings

- Rovazet® significantly reduced LDL-C by 23.5% at 12 weeks and 27.4% at 24 weeks.
- 91.8% of patients reached their LDL-C goals within 24 weeks of treatment.
- Adverse drug reactions were reported in only 2.81% of patients, mostly minor.

## Abstract

Background: Fixed-dose combinations of rosuvastatin and ezetimibe are increasingly used in clinical practice, but real-world data on their effectiveness and safety in large populations remain limited. Methods: This prospective, single-group, open-label, non-interventional observational study was conducted in the Republic of Korea to evaluate the effectiveness and safety of Rovazet® (a fixed-dose combination of rosuvastatin and ezetimibe). Patients were prospectively enrolled from 235 institutions (50 general hospitals and 185 private clinics) as part of routine clinical practice over a five-year period. Lipid profiles and medication compliance questionnaire results were collected at baseline, 12 weeks, and 24 weeks of treatment. Results: A total of 5527 patients with dyslipidemia, the majority were men (53.0%), and the mean age was 60.4 years. Rovazet® significantly reduced low-density lipoprotein cholesterol (LDL-C) by 23.5% at 12 weeks (from 117.47 ± 50.65 mg/dL to 81.14 ± 38.20 mg/dL; p < 0.0001) and by 27.4% at 24 weeks (from 117.47 ± 50.65 mg/dL to 74.52 ± 33.36 mg/dL; p < 0.0001). Total cholesterol was significantly reduced by 17.7% at 12 weeks and by 19.8% at 24 weeks. Rovazet® treatment reduced triglycerides by 4.1% at 12 weeks and by 7.2% at 24 weeks. High-density lipoprotein cholesterol increased by 4.5% at 12 weeks and by 7.9% at 24 weeks following Rovazet® treatment. These changes in lipid profiles were consistent, regardless of cardiovascular risk profiles. By 24 weeks of treatment with Rovazet®, 91.8% of patients had reached their target LDL-C goals. Adverse drug reactions were reported in 2.81% of patients, most of which were minor, indicating that Rovazet® was well tolerated. Conclusions: Rovazet® was effective in improving lipid profiles and well tolerated in Korean adults with dyslipidemia.